You are cordially invited to attend DIA's Biosimilars Conference, October 24-25, in Bethesda, MD.

FDA's final guidance on the naming of biologics (originator and biosimilar), issued this year, is in the implementation process and will have an impact on manufacturers, supply chain, end users, and safety systems. All stakeholders will need systematic approaches to ensure adherence – both prospectively and retrospectively.

How will these changes will affect your systems and products? What will be your next steps?

Our conference brings you the most current science and regulatory developments for biosimilars, as well as the newest thinking and approaches on pharmacovigilance, prescriber and patient education, and access in the US, EU, Canada, and other regions.